Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.4310
-0.0415 (-8.78%)
At close: Jun 12, 2026, 4:00 PM EDT
0.4107
-0.0203 (-4.71%)
After-hours: Jun 12, 2026, 7:57 PM EDT
Nexalin Technology Employees
Nexalin Technology had 8 employees as of December 31, 2025. The number of employees increased by 2 or 33.33% compared to the previous year.
Employees
8
Change (1Y)
2
Growth (1Y)
33.33%
Revenue / Employee
$34,448
Profits / Employee
-$1,041,335
Market Cap
8.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 8 | 2 | 33.33% | 8 | 0 |
| Dec 31, 2024 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2023 | 6 | 0 | - | 6 | 0 |
| Dec 31, 2022 | 6 | -4 | -40.00% | 6 | 0 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 3 | 0 |
| Mar 31, 2022 | 10 | 6 | 150.00% | 2 | 8 |
| Dec 31, 2021 | 10 | 6 | 150.00% | 2 | 8 |
| Sep 30, 2021 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 287 |
| Vivos Therapeutics | 270 |
| VolitionRx | 75 |
| IceCure Medical | 69 |
| Intelligent Bio Solutions | 55 |
| Biomerica | 54 |
| enVVeno Medical | 33 |
| Sintx Technologies | 32 |
NXL News
- 2 days ago - Nexalin Technology completes neurostimulation protocol trial - TheFly
- 2 days ago - Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. - GlobeNewsWire
- 5 days ago - Nexalin Technology Registration statement - Filings
- 5 days ago - Nexalin Technology Quarterly report - Filings
- 8 days ago - Nexalin Technology announces issuance of new U.S. patent - TheFly
- 8 days ago - Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - GlobeNewsWire
- 22 days ago - Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - GlobeNewsWire
- 24 days ago - Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial - GlobeNewsWire